Pacira BioSciences (PCRX) Earnings Date & Reports

Key Takeaways

• Pacira BioSciences (PCRX) is expected to report third-quarter 2026 results after the market close on November 5, 2026, covering the fiscal quarter ended September 30, 2026.
• Analysts' consensus estimates point to adjusted earnings per share (EPS) near $0.73 on revenue of roughly $182.9 million, compared with $0.70 in EPS and $179.5 million in revenue a year earlier.
• The report lands in the shadow of a definitive agreement for Viatris (VTRS) to acquire Pacira for $36.50 per share in cash, a deal valued at about $1.65 billion and expected to close by the end of November 2026.
• Investors will focus on EXPAREL volume trends, momentum in ZILRETTA and iovera, and any updated commentary on full-year 2026 guidance, which management lowered in August to $735 million–$760 million in revenue.
• Pipeline milestones, including the Phase 2 readout for the PCRX-201 gene therapy in knee osteoarthritis, remain secondary catalysts worth watching around the pending transaction.
• For more detail on Pacira's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages available on Tickeron.
• Discover automated trading ideas and market opportunities by exploring Tickeron's Trending AI Robots.

Earnings Context and Why It Matters

Pacira BioSciences is a leader in non-opioid pain management, anchored by EXPAREL, a long-acting local anesthetic used to manage postsurgical pain, alongside ZILRETTA for osteoarthritis-related knee pain and the iovera cold-therapy device. The upcoming report matters because it offers a fresh read on commercial momentum ahead of the company's planned absorption into Viatris. Pacira has beaten consensus EPS estimates in five of its last eight quarters, most recently reporting $0.73 per share for Q2 2026 versus a $0.65 estimate. However, management trimmed its full-year 2026 revenue outlook in August, citing a range of $735 million to $760 million that sat below then-current Street expectations, making this quarter a key checkpoint on the trajectory of its core franchise.

Earnings Expectations

For the third quarter of 2026, Wall Street's consensus projects adjusted EPS near $0.73 on revenue of approximately $182.9 million, according to data compiled by MarketBeat. That would represent modest growth from the prior-year period, when Pacira posted adjusted EPS of $0.70 on revenue of $179.52 million. Estimates vary across providers, in part reflecting differences between GAAP (Generally Accepted Accounting Principles) and non-GAAP measures, but the directional expectation is for roughly flat to low-single-digit revenue expansion.

Beyond the headline figures, investors will watch EXPAREL volume growth, which has been supported by separate Medicare reimbursement for non-opioid pain management following the implementation of the NOPAIN Act (Non-Opioids Prevent Addiction in the Nation Act) in early 2025. Commentary on ZILRETTA and iovera adoption, operating margins, and any adjustment to the company's full-year revenue guidance will also be closely scrutinized. Historically, the stock has reacted to both earnings beats and guidance revisions, though the pending all-cash acquisition at $36.50 per share now anchors the share price near the deal value.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, giving investors a faster way to narrow a broad universe into a focused watchlist. Explore the AI Screener to identify signals that align with your own research process.

Market Reaction and Investor Sentiment

Sentiment around PCRX has been dominated by the announced acquisition rather than the fundamentals of a single quarter. On October 8, 2026, Viatris agreed to acquire all outstanding Pacira shares for $36.50 in cash, valuing the company at approximately $1.65 billion, with the tender offer launched on October 30 and closing expected by the end of November. As a result, the stock has traded near the deal price, leaving limited room for a large fundamental-driven move. Still, any meaningful earnings surprise, a change in full-year guidance, or an update on the transaction timeline could influence short-term trading. Key risk factors heading into the print include the pace of EXPAREL demand, potential cost pressures, and any details management shares about the integration process.

Forward Outlook and Key Factors to Monitor

Looking ahead, the single most important catalyst is the expected completion of the Viatris acquisition before the end of November 2026. Viatris has said the transaction should be immediately accretive to its 2027 financial metrics, with more than $50 million in annual cost synergies expected by the end of 2028.

For the standalone business, investors should monitor whether Pacira reiterates or adjusts its full-year 2026 revenue guidance of $735 million to $760 million. Continued EXPAREL volume growth, supported by the NOPAIN Act's separate reimbursement pathway and a strengthened patent estate, remains central to the company's commercial durability.

On the pipeline front, Pacira has signaled a catalyst-rich period ahead. The Phase 2 readout for PCRX-201, a gene therapy candidate for knee osteoarthritis, and top-line data for other lifecycle programs represent longer-term drivers that Viatris has indicated it will continue to advance after the deal closes. Until the transaction is finalized, the stock is likely to reflect deal value more than quarterly operating results, but the Q3 report still provides the clearest view of the asset Viatris is acquiring.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations